BioSpace News Archive

Theratechnologies Inc. today announced the Company will report financial results and provide a business update for its first quarter ended February 29, 2024, on Wednesday, April 10 at 8:30 a.m. ET.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Thursday, May 2, 2024 at 8:30 a.m. ET.

Alvotech announced today that it will host an audio call with a market update at 12:15 pm GMT / 08:15 am EDT on April 3, 2024.

Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced the company will participate in the 23rd Annual Needham Virtual Healthcare Conference taking place virtually on April 8-11, 2024.

60 Degrees Pharmaceuticals, Inc. announced today that the Company will sponsor a pilot study of tafenoquine , the active molecule in its U.S. Food and Drug Administration (FDA)-approved human malaria prevention medication, ARAKODA®, for the treatment of babesiosis in dogs.

Merus N.V. today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 8:45 a.m. ET.

Bionano Genomics, Inc., announced the publication of a peer-reviewed study that compared optical genome mapping to classical cytogenetic techniques used for analysis of solid tumor cancer samples consisting of soft tissue and bone sarcomas, including fluorescence in situ hybridization and karyotyping.

Annexon, Inc. today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 11:00 a.m. ET.

The leading pharmaceutical company in the Baltics, Grindeks, is developing new products and reinforcing its position not only in European but also global markets.

BioVaxys Technology Corp. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a Patent (“Patent”) for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulate with DPX™.